EGFR and hepatocellular carcinoma: Treatment with the p300 inhibitor C646 induced repression of EGFR transcription activity under CRNDE overexpression, with consequent suppression of HCC proliferation and enhancement of sensitivity to sorafenib, leading to additive effects in prolonging overall survival (Fig. 7H).